

Press Release

Wednesday, October 23, 2013

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531


NSE: STAR

Stelis Biopharma signs a Research Collaboration Agreement with Bio-Scaffold International Pte Ltd to develop scaffolds loaded with BMP and stem cells for various medical applications

October 23, 2013: **Strides Arcolab Limited** (BSE: 532531, NSE: STAR) announced that its biotech subsidiary - **Stelis Biopharma** (previously known as Agila Biotech) today entered into Research Collaboration Agreement with **Bio-Scaffold International Pte Ltd (BSI)**, a Singapore based, start-up Company, to research and develop BMP and stem cell loaded 3D printed devices for various applications in Orthopaedics, Cosmetology/ Plastic and Reconstructive Surgery and Dentistry. The Research will be jointly directed by Dr. Anand Iyer, Ph.D., JD, CEO, Stelis Biopharma and Dr. Margam Chandrasekaran, CEO/ Chief Scientist, Bio-scaffold International Pte. Ltd. and each Company will bear the cost of its contribution to the joint research collaboration.

BSI is a pioneer in the application of 3D printing technology for the development of novel, biocompatible scaffolds. Stelis is a cutting edge biotechnology company whose research and development efforts include the development of drug and stem cell loaded devices for the treatment of various medical conditions. Scientists from Stelis and BSI have developed a framework for initial research collaboration which would include working on multiple areas such as BMP-2/7 heterodimer loaded scaffold for orthopaedic applications and BMP2/ BMP7 loaded scaffolds for spinal fusion etc.

Dr. Iyer and Dr. Chandrasekaran strongly feel that this joint collaboration would help harness the synergies of the two companies in advancing the development of novel 3D printed devices for effectively treating various conditions in the orthopaedic, orthodontic oral/ maxillofacial and plastic/ reconstructive arena.



About Stelis Biopharma / Strides Arcolab Ltd.

Stelis Biopharma Private Limited, India (formerly known as Agila Biotech Private Limited, India), is a wholly owned subsidiary of **Strides Arcolab Limited, India**. **Stelis Biopharma (Malaysia) Sdn Bhd** (formerly known as Agila Biotech (Malaysia) Sdn Bhd), is a wholly owned subsidiary of Stelis Biopharma Private Limited, India.

Stelis Biopharma is building a state-of-the-art R&D in Bangalore (India) to research, and develop biotherapeutic drugs and devices including, but not limited to, biosimilars, biobetters, NBEs, novel formulations and drug loaded devices. The Company is also building a state-of-the-art, fully integrated manufacturing facility at Bio-Xcell's biotechnology park in Nusajaya, within the Iskandar region of Johor, Malaysia for the manufacture of biotherapeutics and devices.

The facility will also provide product and process development and validation services, bioprocess solutions, integrated business services, operational support services, end-user services, leveraging a combination of technology platform and service delivery framework. Stelis will also provide training and support services as well as consultancy in business, marketing and other allied services to other biotechnology companies.


Strides Arcolab Ltd., listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of pharmaceutical products.

The Company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore.

About Bio-scaffold International Pte Ltd.

Bio-scaffold International Pte Ltd (BSI) is a local biomedical technology company focusing on the development of scaffolds for tissue engineering which include repair and replacement of human tissue including bones, ligaments and joints. BSI's ground-breaking innovative technology has led to the development of Alvelac™ which aids in the preservation of alveolar socket after tooth extraction. BSI is working on extending the dental applications and development of new products to address applications in Orthopaedics, Plastic Reconstructive Surgery and allied fields.

Additional information is available at the company's website at www.stridesarco.com.



Contact:

To learn more about this collaboration, please contact:

<p><u>Strides Arcolab Ltd./ Stelis Biopharma</u></p> <p>Dr. Anand Iyer, CEO – Stelis Biopharma Ph: +91 80 6784 0105 Email: anand.iyer@stelis.com</p> <p>Mr. Kannan N: +91 98450 54745 (Investors)</p>	<p><u>PR Consultancy</u></p> <p>Weber Shandwick Kaveri Mandanna Ph: +91 90089 59697 Email: KMandanna@webershandwick.com</p> <p>Mahesh Nair Ph: +91 98803 76648 Email: MNair@webershandwick.com</p>
<p><u>Bio-Scaffold</u></p> <p>Dr. Margam Chandrasekaran, CEO/ Chief Scientist, Bio-scaffold International Pte Ltd Office: +65 6465 4395 Fax +65 6465 5394 Email: chandram@bio-scaffold.com</p>	

